| 摘要 |
<p>Disclosed herein are methods and compositions employing at least one inhibitor of Type I interferon receptor (IFNR) activation, e.g., an IFNR antagonist such as an IFNR1 antagonist, to block the activation of IFNRs in subjects. Such methods may be used to treat persistent or chronic viral infection, e.g., human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and lymphocytic choriomeningitis virus (LCMV); to decrease type I interferon signaling, decrease one or more immunosuppressive factors (e.g., IL-10, PDL1, etc.); increase in the ratio of stimulatory to suppressive APCs; decrease in viral titers; and/or increase the cells associated with cell-mediated immunity (e.g., DC, macrophages, B cells, and NK cells) in subjects having a persistent or chronic viral infection.</p> |
